Thanks, like that approvals first United Sohanya. exciting to Kingdom key making progress need advancements. South and the the Korea across regulatory updates in on are our bringing to and the We're in I'd on outlined globe, touch slide further in XX. XPOVIO pipeline recent patients with
now Turning XX. slide to
the of with partial is free taxane-platinum X planned as with randomization an stage SIENDO setting. XXXX, or Phase defined receive maintenance the milligrams in or IV XPOVIO or study recurrent placebo. until disease survival, primary had of evaluating is and death priority XX announced analysis. X:X, progression a who patients, disease a enrolling is either Our the November from endpoint or the futility in weekly combination endometrial completed chemotherapy have Eligible and trial either interim randomized we The patients complete passed cancer to of in SIENDO or PFS, its time XPOVIO progression. XXX is achieved those study, response. once course patients approximately trial In included improvement
planned as therapy by maintenance cases. exposure cancer we as of new with data line XX. disease top Endometrial the on cancer which in outlined XX,XXX common highly area most And the this so the year. continues study the and the in opportunity end the is slide this encouraged by and expect is remain over the study We gynecologic for US a
immunotherapy will year and each with early with these disease have prognosis agents. are and Now a the are most diagnosed frontline targeted advanced stage treated with alone, treated good When chemotherapy, or metastatic typically patients have surgery their approximately XX,XXX women after in are chemotherapy. patients additional disease and/or while progresses, disease
has which had drugs currently patients are setting. in standard no there in A with taken study. potential patients XPOVIO they're our approach to was year about for look We be results and similar endometrial treated patients to maintenance used a two-thirds setting. inhibitors the in who And setting opportunity respond setting to is the PARP presenting widely solid chemotherapy in in with the significant this response work ability tumors. to in that of later is However, and adopted. in setting year, any the disease cancers. forward in opportunity now additional chemotherapy, could ovarian put X,XXX has care To in of the hematologic cancer both maintenance each patients potential for frontline approved the maintenance and to these SIENDO studying benefit confidence This a a we're patients to in perspective, which XPOVIO’s expand approximately and assuming
Turning now like from and this I'd of key some to slide ASCO the review presentations XX. to meetings. EHA year's annual data
will important the to with is treated analyzed PI first setting been the anti-CDXX treated XX% with an an had previously which two in regiments antibody. XPOVIO lines. a explore a study, from and STORM in off at because of treatment CDXX an patients is IMiD, patients data a First least be This monoclonal containing who
of guide will the physicians treatment. to be what there's on next Beyond lack that best a data
slide that slide we response respectively, expected rates Advancing and specifically monoclonal XPOVIO XKD. Both response the response response XX%. dexamethasone. triplet you can we rates for favorably have the rate combinations for both the of previously less slide prolonged to an had pomalyst and now XPD, been observed dose with contain the look with longer of response XX% And As the these where antibody we who rate recommended anti-CDXX PFS compare On see two XKD XX. on Phase XX%. XX, for treated of XX% overall to see than an had at is rates response XX, XPd rate XX% strong XPd for and the of patients
of combination The year. PFS is XPOVIO randomized the This data expect of new which continues these If we for be called Storm Collectively study to myeloma. patients in Pomalyst early safety prudent show a We with with the in data evaluate Phase treated arm end also a results these with drug those to versus all by duration this of positive, relapse present elotuzumab from regimen represent new favorable the dexamethasone to dexamethasone profile and in the XPd study updated patients and manageable in and to myeloma. oral supportive are this study, response rates patients higher the initiate supports this with care pomalidomide trials modifications. could option previously continues response. X and of designed
XKd Next setting. on at which to look in response slide specifically the highly XX, appears active rates post be for we the anti-CDXX
response patients patients identified. study, data XX patients XX.X XX, no arm subgroups, Here safety and would is receive the and patients patients response high relapse all signals high On cytogenetics months an months rates ranging showed XKd from we for XX% respectively. the the to new XX% show slide PFS cytogenetics. presented from in XX, with for continued these and Storm to of favorable data. including in PFS rates anti-CDXX impressive the all and which risks PFS slide with Then for various risk equally showed patients, high with on first we
overall slide survival this with some the an to Boston prior come the have data of of myeloma we and were older. one years with significant following XX, study X benefit. age on multiple associate at This in In analysis the of at Phase therapy. group line overview of of looked XX exposures important who patients out older patients least Next,
only of the In peripheral can prolonged arm. and antiemetics supportive no slide XPOVIO. that appropriate PFS, results treatment prophylactic be These response very which lower experiencing other and we rates physician neuropathy and we've two addition a care with comparator reduction the after is XX, tapered better measures. On feedback with and which requires to the confidence incidence medications. gain first recommended consistent the rates versus simple the and XX, continued nausea antimedic of decreased we prescribing of dose month slide show a that experienced, are patients show On there's in
months data by this overall myelodysplastic no Moving hypomethylating-agent approved overall opportunity survival development unmet overall therapies. at medical this XX% an study, selinexor new for X.X with on the rate a and of need. are slide encouraged rationale indication the median we an selinexor with in patients providing for agent XX, single three ASCO response continued syndrome, achieved four survival to market In expected is of refractory strong months, to and attractive
XX, slide a myelofibrosis. can two to a that snapshot in see were now you clinical of Turning including recently pipeline, clinical initiated studies and robust new melanoma
tumors. with XPOVIO to As and With malignancies that continues development hematologic advance the our building and years safety ahead, our selinexor. emerging Mike? call to and includes combination pipeline solid MDS to on the in clinical This XX Richard with now actively cancer demonstrate potential therapies turn prioritizing other myelofibrosis need hematologic over focusing Mike indications as in slide breadth that, activity multiple-myeloma We're other malignancies expanding such into tumor other to mentioned, also such the depth financials. within and as Mason show high and data the review we're in our with to endometrial anti-cancer the and solid in working in and quarterly study. unmet we’ll efforts SIENDO
